Quick Answer
Acrivon Therapeutics, Inc. reported Cash and Equivalents of $41.50 million for fiscal year 2025.
Acrivon Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $41.50M | +4.2% |
| 2024 | $39.82M | +10.6% |
| 2023 | $36.02M | +22.0% |
| 2022 | $29.52M | -70.4% |
| 2021 | $99.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.41M | -18.4% | -15.5% |
| June 30, 2025 | $41.90M | -8.9% | +7.0% |
| March 31, 2025 | $39.15M | +59.1% | -1.7% |
| December 31, 2024 | $39.82M | +10.6% | -8.3% |
| September 30, 2024 | $43.41M | +45.4% | -5.6% |
| June 30, 2024 | $46.01M | +20.8% | +87.0% |
| March 31, 2024 | $24.61M | -10.5% | -31.7% |
| December 31, 2023 | $36.02M | +22.0% | +20.6% |
- Acrivon Therapeutics, Inc. showed an increase of +4.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s cash and equivalents has declined by 58.3% (from $99.60 million to $41.50 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: